NT5E and Parkinson disease: Altogether these observations suggest that reduction of CD73 activity, and therefore, adenosine levels, might be a therapeutical tool to decrease neuroinflammation in PD as well as astrogliosis in mesial temporal lobe epilepsy, and likely, to improve cognition in AD and PD.